Novel Ru(II) Complexes as Type-I/-II Photosensitizers for Multimodal Hypoxia-Tolerant Chemo-Photodynamic/Immune Therapy
Molecular Pharmaceutics · 03.02.2025 · 22 (2) · 882-894
DOI: 10.1021/acs.molpharmaceut.4c01046 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 04.01.2025. Verfasst von Xiao Liu und 10 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Jiangsu Province Key Laboratory for Inflammation and Molecular Drug Target, Nantong University, Nantong 226001, Jiangsu Province,…. Hauptthemen laut MEDLINE: Photosensitizing Agents, Photochemotherapy, Ruthenium, Coordination Complexes. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 53 Literaturangaben. Gefördert von: Jiangsu Provincial Key Research and Development Program, Natural Science Research of Jiangsu Higher Education Institutions of China, Graduate Research and Innovation Projects of Jiangsu Province.
Abstract (Originalsprache)
Photodynamic therapy (PDT) is increasingly regarded as an attractive approach for cancer treatment due to its advantages of low invasiveness, minimal side effects, and high efficiency. Here, two novel Ru(II) complexes 8a,b were designed and synthesized by coordinating phenanthroline and biquinoline ligands with Ru(II) center, and their chemo-photodynamic therapy and immunotherapy were explored. Both 8a and 8b exhibited significant phototoxicity against A549 and 4T1 tumor cells via type-I/-II PDT. Among them, 8b exhibited superior oxygen-independent antitumor effects (IC50s = 1.50-1.76 μM) upon laser irradiation, and displayed micromolar-level chemotherapeutic activities, indicating its potential for chemo/photodynamic dual effects. Furthermore, 8b also initiated an ICD cascade, enhancing recruitment and maturation of antigen-presenting cells, thus triggering a CD8+ T cell antitumor immune response. Finally, in vivo antitumor experiments demonstrated that 8b exhibited significant inhibition of lung and breast tumor growth, with inhibition rates of 94.6% and 97.3%, respectively. Therefore, the Ru(II) complexes we designed, as effective type-I/-II photosensitizers and potential immunoactivators, demonstrate multiple antitumor mechanisms, warranting further study.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Jiangsu Province Key Laboratory for Inflammation and Molecular Drug Target, Nantong University, Nantong 226001, Jiangsu Province, China.
- School of Medical, Nantong University, Nantong 226001, Jiangsu Province, China.
- Department of Pharmacy, Department of Neurosurgery, Affiliated Hospital of Nantong University, Nantong 226001, Jiangsu Province, China.
Förderung
- Jiangsu Provincial Key Research and Development Program
- Natural Science Research of Jiangsu Higher Education Institutions of China
- Graduate Research and Innovation Projects of Jiangsu Province
Zitieren
APA
Liu, X., Zheng, H., Peng, Y., Ji, D., Wang, C., Wang, D., Jia, Z., Chang, Y., Cai, X., Wang, L., & Ling, Y. (2025). Novel Ru(II) Complexes as Type-I/-II Photosensitizers for Multimodal Hypoxia-Tolerant Chemo-Photodynamic/Immune Therapy. Molecular Pharmaceutics, 22(2), 882-894. https://doi.org/10.1021/acs.molpharmaceut.4c01046
Vancouver
Liu X, Zheng H, Peng Y, Ji D, Wang C, Wang D, et al. Novel Ru(II) Complexes as Type-I/-II Photosensitizers for Multimodal Hypoxia-Tolerant Chemo-Photodynamic/Immune Therapy. Molecular Pharmaceutics. 2025;22(2):882-894. doi:10.1021/acs.molpharmaceut.4c01046
BibTeX
@article{Liu2025,
author = {Liu, Xiao and Zheng, Hongwei and Peng, Yiqian and Ji, Dongliang and Wang, Chen and Wang, Dezhi and Jia, Zihan and Chang, Yingxue and Cai, Xiangming and Wang, Lei and Ling, Yong},
title = {Novel Ru(II) Complexes as Type-I/-II Photosensitizers for Multimodal Hypoxia-Tolerant Chemo-Photodynamic/Immune Therapy},
journal = {Molecular Pharmaceutics},
year = {2025},
volume = {22},
number = {2},
pages = {882--894},
doi = {10.1021/acs.molpharmaceut.4c01046}
}
EUVIMED